Drug Trial Radar · NCT03120624
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
34
Actual
Start
Sep 15, 2017
Primary completion
Aug 29, 2023
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Apr 19, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone.
Conditions
- Metastatic Endometrial Carcinoma
- Recurrent Endometrial Adenocarcinoma
- Recurrent Endometrial Carcinoma
- Recurrent Endometrial Clear Cell Adenocarcinoma
- Recurrent Endometrial Endometrioid Adenocarcinoma
- Recurrent Endometrial Mixed Cell Adenocarcinoma
- Recurrent Endometrial Serous Adenocarcinoma
- Recurrent Endometrial Undifferentiated Carcinoma
- Recurrent Uterine Corpus Carcinosarcoma
- Stage IV Uterine Corpus Cancer AJCC v7
Interventions
BiopsyProcedure
Undergo image-guided biopsy
Computed TomographyProcedure
Undergo CT
Fluorine F 18 TetrafluoroborateOther
Given IV
Pharmacological StudyOther
Correlative studies
Positron Emission TomographyProcedure
Undergo TFB-PET
Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide SymporterBiological
Given IV
Ruxolitinib PhosphateDrug
Given PO
Technetium Tc-99m Sodium PertechnetateDrug
Given IV
Biospecimen CollectionProcedure
Undergo mouth rinse, buccal swab, urine, and blood sample collection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Who Experienced a Dose-limiting Toxicity (DLT)Time frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.